Therefore, we compared the distribution of MAFB and other macrophage markers, CD68 and CD204, using scRNA sequencing data of lung cancer patients, including normal lung, tumor tissue (stage I and III, n = 7), and advanced tumor tissue (stage IV, n = 4), as reported by Kim et al. (GSE131907) [22]. This evidence concerns the gene CD68 and neoplasm.